CONMED Corporation Announces Leadership Succession

CNMD 10.30.2024

Full Press ReleaseSEC FilingsOur CNMD Tweets

About Gravity Analytica

Recent News

  • 02.05.2025 - Q4 FY24 CONMED Earnings Conference Call
  • 01.13.2025 - J.P. Morgan Healthcare Conference
  • 01.06.2025 - CONMED Corporation to Announce Fourth Quarter 2024 Financial Results on February 5, 2025

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities

LARGO, Fla.--(BUSINESS WIRE)--Oct. 30, 2024--CONMED Corporation(NYSE: CNMD)today announced thatCurt R. Hartmanwill retire as President and Chief Executive Officer (CEO) of the Company, effectiveJanuary 1, 2025.Patrick Beyer, current Chief Operating Officer (COO) of CONMED, will succeedMr. Hartmanas President and CEO and will also be appointed as a member of the Company’s board, effective the same date.

As part of the transition, Lead Independent DirectorMartha Goldberg Aronsonwill assume the position of Chair of the Board onOctober 31, 2024, whileMr. Hartmanwill continue serving as a Director throughDecember 31, 2024.Mr. Hartmanwill remain with CONMED as an advisor through March of 2027.

“On behalf of the entire CONMED Board of Directors, I’d like to thank Curt for his extraordinary contributions to CONMED over the last 10 years,” saidMs. Aronson. “Curt has been instrumental in growing and diversifying the portfolio and expanding our business in key markets, nearly doubling the Company’s revenues and more than doubling its profitability during his tenure. Curt and his team transformed CONMED into a leader in key markets and categories across both General Surgery and Orthopedics, and the Company is in a significantly stronger position than when he joined in 2014. Curt and his team led the acquisitions of several innovative, highly impactful technologies that have been instrumental in driving the Company’s above-market growth and strong profitability. As a result of this transformation, we have helped thousands of patients lead better lives. We truly appreciate Curt’s commitment to CONMED and his support in ensuring a smooth and successful transition. We are very excited to havePat Beyersucceeding Curt as President and CEO. Pat brings a long track record of success, both at CONMED and prior companies, and we look forward to him leading the Company.”

"It has been a privilege to lead CONMED for the past decade, and I am incredibly proud of what we have accomplished together,” saidMr. Hartman. “The team has transformed this business into a world-class organization with a truly innovative portfolio driven by both internal research & development as well as several successful acquisitions. I am thrilled to be succeeded by Pat, as we’ve worked closely together for many years, and he was my first leadership hire when I joined CONMED in 2014. Since assuming the role of Chief Operating Officer this past April, Pat has already made a positive impact on the business, and I look forward to seeing CONMED advance even further under his leadership.”

“I am excited to be appointed as the next President and CEO of CONMED and am extremely grateful to Curt, Martha, and the Board of Directors for the opportunity. I am honored to succeed Curt and am deeply appreciative of his leadership and mentorship over the years we have worked together, including during this transition,” saidMr. Beyer. “I look forward to leading our team in driving further growth and innovation across our businesses and continuing to deliver state-of-the-art products to our customers, allowing them to drive better outcomes for their patients.”

Mr. Beyerjoined CONMED in 2014 as President of International. InOctober 2020,Mr. Beyerwas promoted to President of International and Global Orthopedics, where he took on the added responsibilities for the Company’s Global Orthopedics R&D andU.S.Orthopedics commercial business. In 2022,Mr. Beyerled the process of acquiring both In2Bones and BioRez. InApril 2024,Mr. Beyerwas promoted to the role of Chief Operating Officer (COO), in which he took on additional responsibility for leading the Company’s commercial businesses, as well as Operations, Distribution, Regulatory Affairs / Quality Assurance, and Customer Excellence. Prior to CONMED,Mr. Beyerspent 21 years at Stryker in leadership roles of increasing progression and nearly four years as CEO ofICNet International. He holds a B.A. in Economics fromKalamazoo Collegeand an M.B.A fromWestern Michigan University.Mr. Beyeralso completed the Advanced Management Program atHarvard University.

AboutCONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visitwww.conmed.com.

Forward-Looking Statements

This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year endedDecember 31, 2023, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with theSEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241030725777/en/

CONMED CorporationTodd W. GarnerChief Financial Officer727-214-2975ToddGarner@conmed.com

Source:CONMED Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com